Diffuse large B-cell lymphoma successfully treated with amplified natural killer therapy alone: A case report

Figure 1 Imaging findings at diagnosis. A: Subclavian lymph node enlargement; B: Right axillary lymph node enlargement.

Figure 2 Pathological findings at diagnosis. A: HE ×10; B: HE ×40.

Figure 3 Immunostaining at diagnosis. A: CD20 ×40(+); B: CD79a ×40(+); C: CD10 ×40(+); D: bcl6 ×20(+); E: bcl2 ×20(+).

Figure 4 Course of lactate dehydrogenase, interleukin-2, and amplified natural killer treatment schedule. ANK: Amplified natural killer; IL-2: Interleukin-2; LDH: Lactate dehydrogenase; NK: Natural killer.

Figure 5 Post-treatment course of computed tomography imaging. Three months after treatment, the size of the right axillary and subclavian lymph nodes appears to be gradually reduced; five months later, a marked reduction can be observed. A: July 2022; B: October 2022; C: December 2022; D: February 2023; E: March 2023.

Figure 6 Pathological tissues derived from the patient were subjected to programmed death ligand 1 immunostaining, revealing positive immunostaining. Programmed death ligand 1 × 40.